Honeywell International Inc. announced a tender offer to repurchase up to $3.75 billion of its dollar‑denominated debt, with the offer set to expire on April 9, 2026 and a settlement date around March 24, 2026. The move is part of a broader strategy to lower leverage in preparation for the planned spin‑off of Honeywell Aerospace Inc.
The tender offer will be financed through proceeds from new senior unsecured notes, mirroring a similar approach used in 2016. By buying back debt, Honeywell aims to reduce its total debt load, which stood at $37.03 billion as of December 2025, and improve its debt‑to‑equity ratio, which was 229.6 % at the end of 2025.
Analysts note that the buyback aligns with Honeywell’s ongoing portfolio optimization. The company has been actively managing its capital structure, issuing new debt and refinancing existing obligations, and the current tender offer is a continuation of that trend. The timing also dovetails with the company’s plan to separate its Aerospace business, which is expected to create two more focused entities.
The announcement follows a history of debt‑tender activity, including a 2016 cash tender for notes due 2017‑2019 and an exchange offer in 2017. These actions demonstrate Honeywell’s willingness to use market tools to adjust leverage and maintain a favorable credit profile, a stance that was reinforced by Moody’s positive outlook upgrade in September 2023.
While the tender offer itself does not immediately change Honeywell’s cash position, the expected reduction in debt is projected to strengthen the company’s balance sheet and potentially improve its credit ratings. Investors will watch the settlement of the offer and the subsequent impact on leverage ratios and debt‑service coverage as the company moves toward the Aerospace spin‑off.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.